Prognostic factors determining recurrence in early-stage endometrial cancer


MISIRLIOGLU S., GÜZEL A. B., GULEC U. K., GÜMÜRDÜLÜ D., VARDAR M. A.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, cilt.33, sa.6, ss.610-614, 2012 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 33 Sayı: 6
  • Basım Tarihi: 2012
  • Dergi Adı: EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.610-614
  • Çukurova Üniversitesi Adresli: Evet

Özet

Objective: This study aimed to determine the clinically important prognostic factors for loco-regional or distant recurrence in early-stage endometrial cancer. Materials and Methods: This study complied with the Declaration of Helsinki, and the local ethics committee approved the study: Cases who underwent primary surgery of early-stage endometrial cancer at the Institution from 2000 to 2012 were reviewed retrospectively. Patients who did not detect recurrence were classified as group 1 (n = 200); those who detected recurrence were classified as group 2 (n = 23). Clinically prognostic factors were evaluated by univariate analyses. Results: The average age for group 2 (LUSI) was 63.8 years (p = 0.0001). Patients with grade 3 histology were all detected within group 2 (p = 0.0001). Endometrioid adenocarcinoma displaying squamous differentiation was found with a rate of 58.3% in group 2 (p = 0.0001). Lower uterine segment involvement (LUSI) and lymphovascular space invasion (LVSI) rates were 86.9% in group 2 (p = 0.0001). The rate of tumor size > 2 cm was 56.6% in group 2 (p = 0.0001). The median depth of myometrial invasion (DMI) was 5.1 mm (p = 0.034) and the average in myometrial thickness was 14.5 mm in group H (p = 0.0001). The percentage of myometrial invasion was 35.8% in Group II (p = 0.0001). Tumor free-distance was 9.4 mm in group II (p = 0.0001). Conclusion: Age and clinicopathological parameters of the tumours are significant predictors for recurrence in early-stage endometrial cancer.